40 mg/day vormatrogine for 12 weeks

Phase 3

Praxis Precision Medicines, Inc. (PRAX)

00%

What is LOA?

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Jan '27

PRAXPhase 3$7.9B

40 mg/day vormatrogine for 12 weeks Phase 3 Est. Readout

40 mg/day vormatrogine for 12 weeks• Focal Epilepsy300

Jan 2027~ConfirmedSTALE

CT.gov

00%

Competitive Landscape

1 competitor in Focal Epilepsy

BHVNopakalim

View Full Landscape

Drug Information

Target Indication

Focal Epilepsy

Clinical Trial

NCT07505004

Last updated: 6/26/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

PRAX

Praxis Precision Medicines, Inc.

Pharmaceutical Preparations•North America•NASDAQ

Related Pipeline

1.0mg/kg/day PRAX-562Phase 3

Developmental and Epileptic Encephalopathy 1

PRAX-562Phase 3

SCN2A Encephalopathy

20mg/day PRAX-628 for 6 weeks then 30mg/day PRAX-628 for remaining 6 weeksPhase 3

Focal Seizure

PRAX-114Phase 3

Major Depressive Disorder

1mg elsunersenPhase 3

Epileptic Encephalopathy

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts